Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Wen‐Lin Luo"'
Autor:
Björn Holzhauer, Lisa V. Hampson, John Paul Gosling, Björn Bornkamp, Joseph Kahn, Markus R. Lange, Wen‐Lin Luo, Caterina Brindicci, David Lawrence, Steffen Ballerstedt, Anthony O'Hagan
Publikováno v:
Pharmaceutical Statistics, 2022, Vol.21(5), pp.1005-1021 [Peer Reviewed Journal]
Pharmaceutical companies regularly need to make decisions about drug development programs based on the limited knowledge from early stage clinical trials. In this situation, eliciting the judgements of experts is an attractive approach for synthesisi
Autor:
Lisa V. Hampson, Wen-Lin Luo, Steffen Ballerstedt, Björn Holzhauer, Markus R. Lange, Pritibha Singh, Giovanni Della Cioppa, Joseph Kahn, Björn Bornkamp
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:1050-1060
The point at which clinical development programs transition from early-phase to pivotal trials is a critical milestone. Substantial uncertainty about the outcome of pivotal trials may remain even after seeing positive early-phase data, and companies
Publikováno v:
Lancet (London, England). 400(10355)
Publikováno v:
SSRN Electronic Journal.
Publikováno v:
Chemical Engineering Journal. 456:140948
Autor:
Xiujiang S. Li, Lata Maganti, Tracie L. Miller, Wen-Lin Luo, Henry Rodriguez, Susan J. Lee, Daniel Tatosian, Philip Zeitler, Iain P. Fraser, Jaclyn K. Patterson, Mark S. Kipnes, Naomi D. Neufeld, Jocelyn Gilmartin, S. Aubrey Stoch, Larry A. Fox
Publikováno v:
Pediatric Diabetes. 20:48-56
Objective To evaluate the single-dose pharmacokinetics (PK), pharmacodynamics (PD), and safety of sitagliptin in pediatric patients with type 2 diabetes mellitus (T2DM). Study design This was a randomized, placebo-controlled, double-blind evaluation
Autor:
Robert J Moots, Athena Papas, Thomas Dörner, Benjamin A Fisher, Salvatore De Vita, Thomas Grader-Beck, Simon J. Bowman, Wolfgang Hueber, Monika Sopala, Filipe Barcelos, Hendrik Schulze-Koops, Guido Junge, Wen-Lin Luo, J. Woznicki, Robert I. Fox, Xavier Mariette
Publikováno v:
Lancet (London, England). 399(10320)
Sjögren's syndrome is an autoimmune disease characterised by dry eyes and mouth, systemic features, and reduced quality of life. There are no disease-modifying treatments. A new biologic, ianalumab (VAY736), with two modes of suppressing B cells, ha
Autor:
Robert J Moots, Monika Sopala, Wolfgang Hueber, Xavier Mariette, S. De Vita, Wen-Lin Luo, Hendrik Schulze-Koops, Benjamin A Fisher, Guido Junge, Thomas Grader-Beck, Thomas Dörner, Simon J. Bowman, J. Woznicki, Filipe Barcelos, Athena Papas, Robert I. Fox
Publikováno v:
Annals of the Rheumatic Diseases. 80:593-594
Background:Sjogren’s syndrome (SS) is an autoimmune disease affecting excretory glands and characterised by B-cell hyperactivity. Ianalumab (VAY736) is a human monoclonal antibody to B-cell activating factor receptor, engineered for direct ADCC-med
On the Use of Group Sequential Study Designs for the Test of Bioequivalence for Complicated Products
Publikováno v:
Journal of Pharmaceutical Sciences. 106:3167-3170
A novel modeling approach together with a use of group sequential study design for a complicated triple fixed-dose combination was attempted. Probability of success (POS) was used for determining a weighted average power, where weight was based on av
Autor:
J. Woznicki, Wen-Lin Luo, Athena Papas, Robert I. Fox, H. Schultze-Koops, Monika Sopala, T. Doerner, Wolfgang Hueber, S. de Vita, Guido Junge, Xavier Mariette, Robert J Moots, Benjamin A Fisher, Thomas Grader-Beck, Simon J. Bowman, Filipe Barcelos
Publikováno v:
Revue du Rhumatisme. 87:A7
Introduction Le syndrome de Sjogren primaire (SSp) est une maladie auto-immune multi-organe touchant principalement les glandes exocrines et caracterisee par une hyperactivite des lymphocytes B (LB). Aucun traitement systemique approuve n’est dispo